Myriad Genetics (MYGN) said Tuesday it has partnered with GSK (GSK) to support access to homologous recombination deficiency diagnostic testing for patients with high-grade serous ovarian cancer.
A sponsored testing plan utilizing Myriad's MyChoice HRD Plus and MyChoice CDx Plus Tests is now available in Argentina, Brazil, Chile, Colombia, Egypt, Netherlands, Saudi Arabia, Singapore, and the United Arab Emirates, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments